Overview

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-09-22
Target enrollment:
Participant gender:
Summary
This is the second in-human study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
Phase:
PHASE1
Details
Lead Sponsor:
ReCode Therapeutics